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Abstract
Background: Myasthenia gravis (MG) is an antibody-mediated autoimmune disease of the neuromuscular junction
(NMJ), mostly associated with acetylcholine receptor (AChR) antibodies. Around 5–10 % of MG patients show antibodies
to muscle-specific tyrosine kinase (MuSK). Mesenchymal stem cell (MSC) administration has been shown to ameliorate
muscle weakness in the experimental autoimmune myasthenia gravis (EAMG) model induced by AChR immunization.
Methods: To investigate the efficacy of stem cell treatment in MuSK-related EAMG, clinical and immunological features
of MuSK-immunized mice with or without dental follicle MSC (DFMSC) treatment were compared.
Results: MuSK-immunized mice intravenously treated with DFMSC after second and third immunizations showed
significantly lower EAMG incidence and severity and reduced serum anti-MuSK antibody, NMJ IgG, and C3 deposit
levels and CD11b+ lymph node cell ratios. Moreover, lymph node cells of DFMSC-administered mice showed reduced
proliferation and IL-6 and IL-12 production responses to MuSK stimulation. By contrast, proportions of B and T cell
populations and production of a wide variety of cytokines were not affected from DFMSC treatment.
Conclusions: Our results suggest that DFMSC treatment shows its beneficial effects mostly through suppression of
innate immune system, whereas other immune functions appear to be preserved. Stem cell treatment might thus
constitute a specific and effective treatment method in MuSK-associated MG.
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Background
Myasthenia gravis (MG) is a T cell-dependent and
antibody-mediated autoimmune disease characterized with
fluctuating muscle weakness due to neuromuscular junc-
tion (NMJ) dysfunction mostly induced by acetylcholine re-
ceptor (AChR) antibodies [1]. MG is currently treated with
global immunosuppressants with substantial side effects
including steroids, azathioprine, and other cytotoxic drugs.
Around 5–10 % of MG patients display muscle-specific
tyrosine kinase (MuSK) antibodies. MuSK antibody-
positive MG patients often present with a severe clin-
ical course and higher dosages of immunosuppressants
are required for their management [2], prompting the
innovation of novel therapeutic reagents with specific
mechanisms of action and fewer side effects.
Mesenchymal stem cells (MSCs) are multipotent adult
stem cells. They have been isolated from various sources,
such as cord blood, Wharton’s jelly, the placenta, bone
marrow, teeth, and adipose tissue [3–11].
A promising source of MSCs is dental tissue, which is
easily accessible and can be isolated from many sources
of the orofacial region, such as stem cells isolated from
human exfoliated deciduous teeth (SHEDs), dental pulp
stem cells (DPSCs), dental follicle stem cells (DFSCs),
and periodontal ligament stem cells (PDLSCs) [11–14].
MSCs show expression of embryonic stem cell markers
Oct4, NANOG, SOX2, alkaline phosphatase, and SSEA-
4 in adult MSC populations derived from the bone mar-
row, adipose tissue, dermis, and heart [9–14].
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As a promising therapeutic tool to suppress inflamma-
tion and immunomodulation, MSCs have been widely used
in preclinical treatment studies of several autoimmune dis-
orders [15–21]. Recently, MSCs from bone marrow have
been successfully employed in AChR-induced experimental
autoimmune myasthenia gravis (EAMG) model resulting
in amelioration of muscle weakness and reduction of
AChR-reactive lymphocytes [21]. However, in this previous
study, immunopathogenic aspects of EAMG have not been
comprehensively investigated.
In this study, the efficacy of stem cell treatment has
been tested in MuSK-associated EAMG for the first time
and immunopathogenic features of MSC-treated mice
have been analyzed. Our results suggest that MSC ad-
ministration might constitute a specific and effective
treatment method in MuSK-associated MG.
Methods
Mice and MuSK
Seven- to 8-week-old wild-type C57BL/6 (B6) mice were
purchased from Jackson Laboratories (Bar Harbor, ME,
USA). All animals were housed in the viral antibody-free
barrier facility at the Istanbul University and maintained
according to the Institutional Animal Care and Use Com-
mittee Guidelines. The extracellular domain of human
MuSK (amino acids 1–463, MUSK_HUMAN O15146-3)
was cloned into the pPICZαA vector (Invitrogen, San
Diego, CA, USA) and was expressed in Pichia pastoris host
strain X33 as soluble protein in the yeast culture super-
natant as described previously [22, 23]. The expressed pro-
tein was purified by metal affinity chromatography using
Ni-NTA agarose resin (Qiagen, Valencia, CA, USA), ac-
cording to the manufacturer’s protocol. The purity of
the protein was documented by gel electrophoresis and
western blotting with a commercial anti-human MuSK
antibody (Abcam, Cambridge, UK).
Isolation of dental follicle MSC (DFMSC)
Dental follicles (DF) were collected from the Marmara Uni-
versity Faculty of Dentistry Oral and Maxillofacial Surgery.
The legitimate delegate of all patients provided informed
consent according to the guidelines of the Ethics Commit-
tee of the Marmara University Medical Faculty in Istanbul,
Turkey (09.2014.0015/70737436-050.06.04). These follicles
were transported in Dulbecco’s phosphate-buffered saline
(DPBS, Gibco, Grand Island, NY 14072, USA) containing
1 % penicillin/streptomycin (Gibco, USA). All laboratory
work was performed in a laboratory in the Department of
Pediatric Allergy-Immunology, Marmara University Re-
search Hospital.
Follicles were isolated under sterile conditions. They were
enzymatically treated with 3 mg/ml collagenase type I
(Gibco, USA) for 45 min at 37 °C to completely digest pulp
and follicle tissue. Then, 3 ml of Dulbecco’s modified
Eagle’s medium (DMEM, Gibco, USA) supplemented with
10 % fetal bovine serum (FBS, Gibco, USA) and 1 % penicil-
lin/streptomycin was added to digest the pulp and follicle
tissue followed by centrifugation at 1200 rpm for 5 min.
Cell pellets were obtained, and the supernatant was aspi-
rated. DFMSCs were cultivated in T-25 flasks in a 5 % CO2
atmosphere under 37 °C in culture medium composed of
DMEM, 10 % FBS, and 1 % penicillin/streptomycin. The
stem cells were washed with DPBS and provided with fresh
culture medium. The culture medium was changed every 3
to 4 days until the cells reached confluence. The cells were
detached with 0.25 % trypsin-EDTA (Gibco, USA) when
they reached 70–80 % confluence. Adherent cells cultured
for 3 passages were characterized and analyzed for specific
surface markers. The cellular analyses and differentiation
were performed using flow cytometry.
Flow cytometry analysis of DFMSCs
To analyze the cell surface antigen expressions, the cells
from the third passage were used. DFMSCs were incubated
with antibodies for human CD73 phycoerythrin (PE), CD90
PE, CD146 fluorescein isothiocyanate (FITC), CD29 allo-
phycocyanin (APC), CD105 PE, CD45 FITC, CD34 PE,
CD14 PE, CD25 APC, and CD28 PE (BD Biosciences, San
Diego, CA, USA) at room temperature in the dark. Con-
trol antibodies were PE-conjugated or FITC-conjugated
and APC-conjugated mouse IgG1 and mouse IgG2 (BD
Biosciences, San Diego, CA, USA). The flow cytometry re-
sults were analyzed using BD FACS Calibur.
Differentiation of stem cells
To induce osteogenic (MesenCult, Stemcell Technolo-
gies, North America), adipogenic, and chondrogenic dif-
ferentiation, a human MSC functional identification kit
(Gibco, Grand Island, USA) was used. For differenti-
ation, the cells were plated in 6-well plates (5 × 104 cell/
well), and the differentiation medium was prepared ac-
cording to the manufacturer’s instructions and changed
3 times per week. After 14 days, the adipocytes and
chondrocytes were stained with Oil Red O and Alcian
blue, respectively, and after 28 days, the osteocytes were
stained with Alizarin red [24].
Real-time PCR analysis
Total RNA was isolated from 1 × 106 DFMSCs at pas-
sage 3 using a high pure RNA isolation kit (Roche,
Mannheim, Germany) according to the manufacturer’s
instructions. One microgram of total RNA was con-
verted to cDNA using a Transcriptor first-strand cDNA
synthesis kit (Roche Mannheim, Germany). Equal amounts
of cDNA were used for the real-time amplification of the
target genes according to the manufacturer’s recom-
mendations using a LightCycler 480 Real-Time PCR
System (Roche Diagnostic, Mannheim, Germany). The
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gene expression of specific markers for MSCs, includ-
ing alkaline phosphatase (ALPL), runt-related transcrip-
tion factor 2 (RUNX2), NANOG, NESTİN, NOTCH, and
dentin sialophosphoprotein (DSPP), was quantified relative
to the housekeeping gene glyceraldehyde 3-phosphate de-
hydrogenase (GAPDH). The RT-PCR conditions were as
follows: pre-incubation for 10 min at 95 °C for 1 cycle;
amplification for 10 s at 95 °C, 60 °C for 30 s, 72 °C for 1 s
for 45 cycles; and cooling for 10 s at 40 °C for 1 cycle. The
reaction mixture lacking cDNA was used as a negative con-
trol in each run. The real-time PCR results were analyzed
using LightCycler software (version 2).
Induction and clinical evaluation of EAMG
A total of 20 B6 mice were anesthetized and immunized
with 30 μg of MuSK emulsified in complete Freund’s ad-
juvant (CFA, Difco, Detroit, MI, USA) s.c. at four sites
(two hind footpads and shoulders) on day 0 and were
boosted with the same amount of MuSK in CFA s.c. at
four sites on the back on days 28 and 56. An additional
20 control mice were immunized with only CFA. The
number of cells to be administered per injection was de-
termined during optimization studies. During these
studies, clinical results obtained with mouse compact
bone MSC and DFMSC treatments were also compared
(Additional file 1: Table S1). The DFMSCs were freshly
prepared before each injection. They were trypsinized and
washed for two times with PBS, and 1 × 106 DFMSCs were
administered intravenously in 1 h via an insulin syringe
from the tail vein twice (7 days after second and third im-
munizations) to MuSK +CFA (MuSK-SC, n = 10) and only
CFA (CFA-SC, n = 10) -immunized mice. The remaining
mice from MuSK +CFA (n = 10) and only CFA (n = 10)
groups were used as non-DFMSC treatment controls and
were treated with PBS only. Mice were terminated 28 days
after the third immunization.
For clinical examination, mice were left for 3 min on a
flat platform and were observed for signs of EAMG. Clin-
ical muscle weakness was graded as follows: grade 0, mouse
with normal posture, muscle strength, and mobility; grade
1, normal at rest, with muscle weakness characteristically
shown by a hunched posture, restricted mobility and diffi-
culty raising the head after exercise that consisted of 30
paw grips on a cage top grid; grade 2, grade 1 symptoms
without exercise during the observation period on a flat
platform; grade 3, dehydrated and moribund with grade 2
weakness; and grade 4, dead.
Inverted screen test was administered for quantitative
evaluation of muscle weakness. Mice were placed in the
center of a screen of wire mesh, which was immediately
rotated to the inverted position and held steadily 50 cm
above a padded surface. The time at which the mouse
fell off was noted with an endpoint of 300 s. The re-
corded time was compared for statistical significance
among treatment and control groups.
ELISA for anti-MuSK Ig isotypes
Mice were bled from the tail vein during termination. Sera
were evaluated for anti-MuSK IgG, IgG1, IgG2b, IgG3, and
IgM levels. Affinity-purified human MuSK (1 μg/ml) was
coated onto 96-well microtiter plates in 0.1 M carbonate
bicarbonate buffer overnight at 4 °C. Diluted serum sam-
ples of 100 μl (1:1000) were added and incubated at 37 °C
for 90 min. Horseradish peroxidase (HRP)-conjugated
anti-mouse IgG, IgG1, IgG2b, IgG3, and IgM (Abcam)
(1:10,000) were added and then incubated at 37 °C for
90 min. Subsequently, the peroxidase indicator substrate
2,2′-azinobis-(3-ethylbenzothiazoline 6-sulfonate) substrate
Fig. 1 Representative flow cytometry analysis of cell surface markers in dental follicle mesenchymal stem cells (DFMSCs). Representative flow
cytometry analysis of cell-surface markers on DFMSCs in P3
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(ABTS) solution in 0.1 M citric buffer (pH 4.35) was added
in the presence of H2O2, and the mixture was allowed to
develop color at room temperature in the dark. Plates were
read at a wavelength of 405 nm.
Immunofluorescence for NMJ IgG and C3 deposits
Sections (10 μm thick) were obtained from forelimb muscle
samples of mice, frozen in liquid nitrogen, and stored at
−80 °C. Slides were fixed in cold acetone and blocked in
10 % normal goat serum in PBS. After washing with PBS,
the sections were incubated with tetramethylrhodamine-
conjugated bungarotoxin (BTx) (Molecular Probes, Eugene,
OR) (1/500 dilution) for 1 h at room temperature to label
the NMJ. Sections were then incubated for 1 h at room
temperature with FITC-conjugated antibodies to mouse
IgG or complement factor C3 (Abcam) (diluted 1/1000) to
colocalize IgG and C3 deposits in NMJ. The sections were
washed and viewed in a fluorescence microscope (Olympus
IX-70). The number of IgG- and C3-positive BTx binding
sites was counted in five muscle sections from each mouse.
The percentages of NMJs with deposits in each muscle sec-
tion were calculated by totaling the numbers of deposits
divided by the numbers of BTx-labeled sites, times 100.
Flow cytometry for lymph node cell subpopulations
In immunization-based EAMG models, antigens are
injected subcutaneously to body parts that are in close
proximity with the lymph nodes. As a result, immuno-
pathogenic processes leading to antibody formation and
muscle weakness predominantly occur in the local drain-
ing lymph nodes. Therefore, in our study, all immunopath-
ological studies were conducted using lymph node cells.
For this purpose, inguinal, popliteal, and axillary lymph
node cells were collected at the termination of the experi-
ment. Single-cell suspensions of lymph node cells were
incubated for 30 min with one of the following anti-mouse
antibodies: PE-conjugated anti-CD4, anti-CD19, anti-
CD11b, and anti-CD3 and FITC-conjugated anti-CD8 (all
from BD PharMingen). PE- or FITC-conjugated isotypes
were used for controls. Cells were washed twice and then
were fixed with 2 % paraformaldehyde and analyzed by
flow cytometry (BD Biosciences).
Lymphocyte proliferation assay
The percentage of proliferating cells in response to MuSK
stimulation was measured by carboxyfluorescein succinimi-
dyl ester (CFSE) labeling. Lymph node cells (6 × 105 cells/
well) were seeded in triplicate into 48-well plates in 0.5 ml
of culture medium [RPMI 1640 supplemented with 10 %
fetal calf serum, penicillin G (100 U/ml) streptomycin
(100 μg/ml), L-glutamine (2 mM), 2-mercaptoethanol (3 ×
10−5 M) and HEPES buffer (25 mM)] in the absence or
presence (5 or 15 μg) of MuSK. After being cultured for
4 days at 37 °C in humidified 5 % CO2-enriched air, cells
Fig. 2 Alizarin red staining of osteogenic-induced dental follicle mesenchymal stem cells (DFMSCs) (left), oil red staining of adipogenic-induced
DFMSCs (middle), and Alcian blue staining of chondrogenic-induced and DFMSCs (right) (magnification for all, ×100)
Fig. 3 Gene expression of specific markers for dental follicle
mesenchymal stem cells (DFMSCs), including alkaline phosphatase
(ALPL), runt-related transcription factor 2 (RUNX2), NANOG, NESTİN,
NOTCH, and dentin sialophosphoprotein (DSPP) in reference to
housekeeping gene glyceraldehyde 3-phosphate dehydrogenase
(GAPDH), was performed. Vertical bars indicate standard errors
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were labeled with CFSE-FITC (5 μmol/L; Molecular Probes
Europe, BV, Leiden, The Netherlands) and analyzed by flow
cytometry (BD Biosciences).
Cytokine measurements in culture supernatants
Lymph node cells (2 × 105 cells/well) were seeded in
triplicate into 96-well, round-bottomed microtiter plates
in 0.2 ml of culture medium in the absence or presence
(5 or 15 μg) of MuSK. The cells were cultured for 48 h
at 37 °C in humidified 5 % CO2-enriched air. Superna-
tants were collected and stored at −80 °C until analyzed.
The supernatant levels of IL-4, IL-10, IL-13, IFN-γ, IL-
12, IL-21, IL-17, IL-6, TGF-β, and TNF-α were mea-
sured by ELISA kits (Invitrogen, Carlsbad, CA, USA),
according to the manufacturer’s instructions.
Statistical analysis
Clinical EAMG incidences were compared using the
Fisher’s exact test. Clinical grades were compared by
Kruskal–Wallis test and Dunn’s post hoc test. All other
parameters were compared using ANOVA (and Tukey’s
post hoc test). p values less than 0.05 were considered
statistically significant.
Results
Isolation, characterization, and differentiation of DFMSCs
DFMSCs attached sparsely to the culture flasks and exhib-
ited a fibroblast-like and spindle-shaped morphology dur-
ing the early days of incubation. The DFMSCs began to
proliferate in approximately 2 days and gradually formed
small colonies. The DFMSCs reached 70 % confluency
in the primary culture 5–6 days after being plated in
Fig. 4 Average clinical grades (a) and inverted screen hang times (b) of MuSK- and CFA-immunized mice with or without dental follicle mesenchymal
stem cell (DFMSC) treatment. MuSK-immunized mice treated with DFMSC (MuSK-SC) showed significantly reduced clinical grades and increased screen
hang time than non-treated mice. Asterisks only denote significant differences between MuSK and MuSK-SC groups as calculated by post hoc analysis.
*p < 0.05; **p < 0.01 by Kruskal–Wallis and Dunn’s post hoc test or ANOVA and Tukey’s post hoc test, as required. Vertical bars indicate standard errors.
Note that in Fig. 4a, the values of CFA and CFA-SC groups overlap since the average clinical grade for both groups is 0 (no disease) at all time points
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their first passages (P1). Most of the DFMSCs exhibited
fibroblast-like morphology in the later passages. Then,
immunophenotyping and differentiation of the third cell
passage were observed. The DFMSCs were analyzed via
flow cytometry. These cells exhibited positive staining for
CD29, CD73, CD90, CD105, and CD146 but were nega-
tive for CD14, CD25, CD28, CD34, and CD45 (Fig. 1).
The DFMSCs differentiated into osteocytes, adipocytes,
and chondrocytes. First, the osteogenic differentiation of
stem cells were evaluated for osteoblast mineralization in
the matrix with the stimuli of human osteoblast medium
and Alizarin red staining was used for the calcium depos-
ition. The DFMSCs were stained with Alizarin red, and the
cells formed calcified bone nodule structures (Fig. 2, left
panel). Next, the in vitro adipogenic differentiation capabil-
ity was assessed by culturing the cells in adipogenic induc-
tion medium and staining with Oil Red O. Intracellular
lipid droplets were observed in these cells (Fig. 3, middle
panel). Finally, the chondrogenic differentiation was evalu-
ated by using Alcian blue. Chondrogenic differentiation
medium was used at the end of the culture period. Alcian
blue was used to observe proteoglycans in the matrix of
cartilage. We observed proteoglycans in blue color in the
matrix (Fig. 2, right panel).
We also analyzed the gene expression of specific
markers in DFSCs by RT-PCR. The DFSCs expressed
ALPL, RUNX2, NANOG, NESTİN, NOTCH, and DSPP
genes (Fig. 3).
DFMSC administration ameliorates clinical symptoms of
MuSK-related EAMG
At termination, 8 of 10 MuSK-immunized mice and only 4
of 10 of the MuSK-SC group had developed myasthenic
Fig. 5 Serum anti-MuSK antibody levels in MuSK- and CFA-immunized mice with or without dental follicle mesenchymal stem cell (DFMSC) treatment.
MuSK-immunized mice with DFMSC treatment (MuSK-SC) showed significantly lower anti-MuSK IgG, IgG1, IgG2b, and IgG3 levels than non-DFMSC-treated
mice (MuSK). Asterisks only denote significant differences between MuSK and MuSK-SC groups as calculated by post hoc analysis. *p< 0.05; **p< 0.01 by
ANOVA and Tukey’s post hoc test. Vertical bars indicate standard errors
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muscle weakness (grade ≥ 1) (p = 0.034). Moreover, starting
from week 5 after first immunization, mice from the
MuSK-SC group displayed significantly lower average clin-
ical grades than MuSK-immunized mice with no DFMSC
treatment. Likewise, starting from week 6, DFMSC-treated
mice showed significantly increased screen hang time than
non-treated mice. CFA-immunized mice with or without
DFMSC treatment did not show any signs of muscle weak-
ness, as expected (Fig. 4).
DFMSC administration ameliorates immunopathological
findings of MuSK-related EAMG
Tukey’s post hoc analysis indicated that MuSK-SC mice
had significantly lower serum anti-MuSK IgG, IgG1, IgG2b,
and IgG3 levels than MuSK-immunized mice with no
DFMSC treatment, whereas anti-MuSK IgM levels of
both MuSK groups were comparable (Fig. 5). Likewise,
MuSK-SC mice were found out to display significantly
lower percentages of NMJ IgG and C3 deposits than
MuSK-immunized mice with no DFMSC treatment by
Tukey’s post hoc analysis (Fig. 6a, b). Muscle sections
of mice from CFA and CFA-SC groups did not show
considerable NMJ deposits (not shown).
When lymph node cell subpopulations were analyzed by
flow cytometry, CD11b+ cells were discovered to be sig-
nificantly suppressed in both MuSK-SC and CFA-SC mice
as compared to MuSK- or CFA-immunized mice with no
DFMSC treatment. MuSK-SC and CFA-SC groups also
showed trends towards reduced CD3+ cell proportions,
although these differences did not attain statistical sig-
nificance. There were no significant differences between
percentages of CD4+, CD8+, and CD19+ cells among
groups (Fig. 7).
Fig. 6 Assessment of frozen muscle samples of MuSK- and CFA-immunized mice with or without dental follicle mesenchymal stem cell (DFMSC)
treatment by immunofluorescence studies showed reduced neuromuscular junction (NMJ) IgG and C3 deposit proportions in MuSK-immunized
mice with DFMSC treatment (a). Representative pictures of muscle sections stained for C3 and IgG (green fluorescence) and bungarotoxin (BTx) for
colocalization of the NMJs (red fluorescence) (magnification for all, ×100). The immunofluorescence data represent one of 5 sections for each mouse
(b). Asterisks only denote significant differences between MuSK and MuSK-SC groups as calculated by post hoc analysis. *p < 0.05; **p < 0.01 by ANOVA
and Tukey’s post hoc test. Vertical bars indicate standard errors
Ulusoy et al. Journal of Neuroinflammation  (2015) 12:231 Page 7 of 12
DFMSC administration suppresses proliferation and
cytokine production responses of lymph node cells
Lymph node cell proliferation in response to 5 and 15 μg
of MuSK stimulation was measured by CFSE assay. Both
MuSK and MuSK-SC groups showed proliferation re-
sponses, whereas no notable response was observed in
CFA and CFA-SC groups, as expected. Lymph node cells
of MuSK-immunized mice with no DFMSC treatment
showed more distinct proliferation responses than those
of MuSK-SC mice (Fig. 8, upper panel). Stimulation in-
dexes were calculated by dividing proliferation values of
MuSK-stimulated cells by proliferation values of non-
stimulated cells. Stimulation indices of MuSK-SC mice
were statistically comparable to those of CFA-immunized
mice, whereas MuSK-immunized mice with no DFMSC
treatment showed significantly higher stimulation indices
than other immunization groups (p = 0.01 and p = 0.03 for
5 and 15 μg MuSK stimulations, respectively, by ANOVA).
Tukey’s post hoc analysis showed significant differences
for comparisons between the non-DFMSC-treated MuSK
group and other groups (p < 0.05 for all comparisons)
(Fig. 8, lower panels).
Cytokine production responses to MuSK stimulation
were also evaluated by measuring cytokine levels in super-
natants of cultured lymph node cells. MuSK-immunized
mice that were not treated with DFMSCs showed signifi-
cantly higher IL-6 and IL-12 levels than other groups. Al-
though MuSK-SC mice had also relatively higher IL-6 and
IL-12 production levels than CFA-immunized mouse
groups, these differences did not attain statistical signifi-
cance (Fig. 9). There were no significant differences among
MuSK-immunized mice with or without DFMSC treat-
ment by means of supernatant levels of IL-4, IL-10, IL-13,
IFN-γ, IL-21, IL-17, TGF-β, and TNF-α (not shown). Both
MuSK-SC and non-DFMSC-treated MuSK-immunized
mice showed significantly higher IL-4 and IL-10 levels
than non-DFMSC-treated CFA and CFA-SC mice, whereas
levels of other cytokines were comparable among all groups
(not shown).
Discussion
MSC administration has previously been shown to reduce
clinical severity, serum antibody levels, and lymphocyte
proliferation in the EAMG model induced by AChR
immunization [21]. In this study, we have shown for the
first time that DFMSC administration also ameliorates
clinical and basic immunopathological findings of EAMG
induced by MuSK immunization. In consistency with the
previous report, DFMSC-treated mice did not only have
lower clinical scores than untreated mice, but they also ex-
hibited reduced anti-MuSK IgG levels, NMJ deposits, and
lymph node cell proliferation capacity in response to
MuSK stimulation. In line with EAMG studies, a single
patient with AChR antibody-positive MG and motor neu-
ronopathy has benefited from autologous bone marrow-
derived MSC treatment [25], corroborating the notion
that MSC may be effectively used as a potential future
treatment method for MG patients.
In addition to previous EAMG studies, our studies also
suggest that MSCs exert their beneficial effects presumably
through suppression of CD11b+ cells. This marker is pre-
dominantly expressed by cells from the myeloid lineage and
innate immune system displaying functions such as phago-
cytosis, antigen presentation, and neutrophil aggregation
[26–29]. In the lymph node, CD11b is expressed by den-
dritic cells [27, 29, 30], which are known to play a crucial
role in EAMG pathogenesis through presentation of NMJ
antigens to lymphocytes and consequent activation of self-
Fig. 7 Lymph node cell proportions of MuSK- and CFA-immunized mice with or without dental follicle mesenchymal stem cell (DFMSC) treatment.
MuSK-immunized and CFA-immunized mice treated with DFMSC showed significantly reduced CD11b+ cell percentages than non-SC-treated mice.
*p < 0.05 by ANOVA and Tukey’s post hoc test. Vertical bars indicate standard errors
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reactive T and B cells [31]. Therefore, as expected, treat-
ment methods based on suppression of dendritic cell
functions have effectively inhibited EAMG development
in experimental models [31, 32]. Fcγ receptor knockout
mice exhibiting impaired dendritic cell phagocytosis func-
tions are known to be resistant to EAMG induction [33].
Moreover, DFMSCs have previously been shown in differ-
ent animal models to preferentially inhibit cytokine secre-
tion by dendritic cells and alter dendritic cell functions
[34, 35]. It is thus tempting to speculate that DFMSC treat-
ment ameliorates myasthenic muscle weakness through
suppression of CD11b+ dendritic cells. However, CD11b
is also expressed by monocytes, granulocytes, macro-
phages, and natural killer cells [26–29], all of which
might potentially participate in EAMG pathogenesis.
Therefore, exact significance of CD11b+ cell suppres-
sion and distinct cell populations involved in DFMSC-
mediated EAMG amelioration need to be further stud-
ied through screening of an extensive panel of innate
immunity markers by flow cytometry methods.
Notably, in our study, production of several cytokines
primarily secreted by T and B cells were unaffected by
DFMSC treatment. By contrast, the only two cytokines
(IL-6 and IL-12) that were suppressed by DFMSC treat-
ment are predominantly produced by myeloid cell lineage
[36, 37]. Both IL-6 and IL-12 knockout mice have been
shown to display significant resistance to EAMG in-
duced by AChR immunization. Moreover, in resem-
blance to DFMSC-treated mice, both knockout mouse
strains showed reduced antibody production, NMJ de-
posits, and lymphocyte proliferation capacity following
EAMG induction [38, 39]. Although the significance of
these two cytokines in MuSK-related MG is not well
known, treatment methods based on IL-6 and IL-12
Fig. 8 The percentage of proliferating cells in response to MuSK stimulation as measured by carboxyfluorescein succinimidyl ester (CFSE) labeling
(upper panel). Lymph node cells of MuSK-immunized but not CFA-immunized mice showed significant proliferation by MuSK stimulation. Proliferation
was less pronounced in MuSK-immunized mice treated with dental follicle mesenchymal stem cell (DFMSC) than those with no DFMSC treatment.
Stimulation indices were analyzed by dividing lymph node cell percentages obtained by MuSK stimulation (red or yellow bars) by percentages obtained
by no stimulation (blue bars). Only MuSK-immunized mice with no MSC treatment showed significantly increased indices, whereas MuSK-SC mice had
comparable stimulation indices to CFA-immunized mice (lower panels). *p < 0.05; **p < 0.01; ***p < 0.001 by ANOVA and Tukey’s post hoc test. Vertical
bars indicate standard errors
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inhibition might presumably prove beneficial for MuSK
antibody-positive MG patients, as well. Notably, despite
exhibiting increased IL-4 and IL-10 levels as compared
to CFA-immunized mice (as reported previously [40]),
DFMSC-treated mice showed lower EAMG severity
than non-DFMSC-treated mice, implying that non-
Th2-type innate immunity also participates in MuSK-
associated EAMG. Therefore, combined inhibition of
Th2 immunity and the innate immune system might be
required for effective treatment of MuSK antibody-
positive MG patients.
Conclusions
Although we have screened a broad panel of lymph node
cells and cytokines, we have seen significant suppression
only in very selective immune functions following DFMSC
Fig. 9 Cultured and MuSK- or non-stimulated lymph node cells of MuSK-immunized mice with no dental follicle mesenchymal stem cell (DFMSC)
treatment showed significantly more IL-6 and IL-12 production than those of DFMSC-treated MuSK-immunized and CFA-immunized mice. **p < 0.01;
***p < 0.001 by ANOVA and Tukey’s post hoc test. Vertical bars indicate standard errors
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administration. Thus, overall, our findings emphasize that
in contrast with immunosuppressants currently in use for
MG management, DFMSC treatment has very specific ef-
fects on the immune system and nevertheless achieves a
significant amelioration in clinical symptoms. This aspect
of DFMSC treatment is particularly important in the man-
agement of MuSK antibody-positive MG patients, who
often need to receive high dosages of cytotoxic medica-
tions. Our findings have also emphasized once again the
importance of antigen-presenting cells and innate immune
system cells in autoimmunity and suppression of these
cells in treatment of autoimmune disorders. It is thus war-
ranted to further study the impact of the interplay be-
tween different stem cell treatment models and innate
immune system on MG pathogenesis.
Additional file
Additional file 1: Table S1. Clinical incidences, average clinical grades,
and inverted screen hang times of MuSK-immunized mice treated with
different mesenchymal stem cell (MSC) types and cell numbers during
optimization studies. The values were obtained at termination (28 days
after the third MuSK immunization) and each experiment was done with
10 mice per mouse group. Note that lowest experimental autoimmune
myasthenia gravis (EAMG) clinical scores were obtained with administration
of dental follicle MSCs and with 1 × 106 cells per injection (two injections in
total). Immunization and MSC injection were done as described in the
“Methods” section. (DOC 29 kb)
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